Share This Article:

Biological agents in the treatment of uveitis

Abstract Full-Text HTML XML Download Download as PDF (Size:216KB) PP. 64-72
DOI: 10.4236/abb.2013.48A2009    3,669 Downloads   5,574 Views   Citations

ABSTRACT

Inflammatory uveitis is a difficult condition to treat. Recently, a new class of drugs obtained by a biological process and therefore defined as “biologics” has been successfully used in the treatment of immunemediated rheumatic diseases. These drugs target different pro-inflammatory cytokines including tumor necrosis factor-α, interleukin-1 and interleukin-6, or immune effector cells including B and T lymphocytes. Their use has been then extended to different forms of uveitis resistant to standard therapy in small uncontrolled trials, with general and unexpected efficacy. The present review analyzes the literature on treatment of uveitis with the biologics currently available for the treatment of inflammatory rheumatic diseases. We used PubMed search engine as the main source of information. Among the papers included in the reference list, a particular emphasis was given on articles published during the last 5 years.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Paroli, M. , Abbouda, A. , Abicca, I. , Sapìa, A. and Paroli, M. (2013) Biological agents in the treatment of uveitis. Advances in Bioscience and Biotechnology, 4, 64-72. doi: 10.4236/abb.2013.48A2009.

References

[1] Durrani, O.M., Meads, C.A. and Murray, P.I. (2004) Uveitis: A potentially blinding disease. Ophthalmologica, 21, 8223-8236.
[2] Szekanecz, Z., Szanto, S., Szabo, Z., Vancsa, A., Szamosi, S., Bodnar, N., et al. (2010) Biologics-beyond the joints. Autoimmunity Reviews, 9, 820-824. doi:10.1016/j.autrev.2010.07.011
[3] Bell, G.M., Reynolds, G. and Isaacs, J.D. (2011) Biologic therapies in non-rheumatic diseases: Lessons for rheumatologists? Nature Reviews Rheumatology, 7, 507-516. doi:10.1038/nrrheum.2011.106
[4] Hyrich, K.L., Watson, K.D., Isenberg, D.A. and Symmons, D.P. (2008) The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford), 47, 1441-1443. doi:10.1093/rheumatology/ken242
[5] Kahn, P., Weiss, M., Imundo, L.F. and Levy, D.M. (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology, 113, 860-864.
[6] Emi Aikawa, N., de Carvalho, J.F., Artur Almeida Silva, C. and Bonfa, E. (2010) Immunogenicity of Anti-TNFalpha agents in autoimmune diseases. Clinical Reviews in Allergy & Immunology, 38, 82-89. doi:10.1007/s12016-009-8140-3
[7] Aaltonen, K.J., Virkki, L.M., Malmivaara, A., Konttinen, Y.T., Nordstrom, D.C. and Blom, M. (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One, 7, e30275. doi:10.1371/journal.pone.0030275
[8] Smith, J.R., Levinson, R.D., Holland, G.N., Jabs, D.A., Robinson, M.R., Whitcup, S.M., et al. (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis & Rheumatism, 45, 252-257. doi:10.1002/1529-0131(200106)45:3<252::AID-ART257>3.0.CO, 2-5
[9] Sfikakis, P.P., Theodossiadis, P.G., Katsiari, C.G., Kaklamanis, P. and Markomichelakis, N.N. (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet, 358, 295-296. doi:10.1016/S0140-6736(01)05497-6
[10] Accorinti, M., Pirraglia, M.P., Paroli, M.P., Priori, R., Conti, F. and Pivetti-Pezzi, P. (2007) Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease. Japanese Journal of Ophthalmology, 51, 191-196. doi:10.1007/s10384-006-0425-y
[11] Tugal-Tutkun, I., Mudun, A., Urgancioglu, M., Kamali, S., Kasapoglu, E., Inanc, M., et al. (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: An openlabel trial. Arthritis & Rheumatism, 52, 2478-2484. doi:10.1002/art.21231
[12] Russell, A.I., Lawson, W.A. and Haskard, D.O. (2001) Potential new therapeutic options in Behcet’s syndrome. BioDrugs, 15, 25-35. doi:10.2165/00063030-200115010-00003
[13] Pato, E., Munoz-Fernandez, S., Francisco, F., Abad, M.A., Maese, J., Ortiz, A., et al. (2011) Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Seminars in Arthritis and Rheumatism, 40, 314-323. doi:10.1016/j.semarthrit.2010.05.008
[14] Evereklioglu, C. (2011) Ocular Behcet disease: current therapeutic approaches. Current Opinion in Ophthalmology, 22, 508-516. doi:10.1097/ICU.0b013e32834bbe91
[15] Handa, T., Tsunekawa, H., Yoneda, M., Watanabe, D., Mukai, T., Yamamura, M., et al. (2011) Long-term remission of ocular and extraocular manifestations in Behcet’s disease using infliximab. Clinical and Experimental Rheumatology, 29, S58-63.
[16] Keino, H., Watanabe, T., Taki, W. and Okada, A.A. (2011) Effect of infliximab on gene expression profiling in Behcet’s disease. Investigative Ophthalmology & Visual Science, 52, 7681-7686. doi:10.1167/iovs.11-7999
[17] Keino, H., Okada, A.A., Watanabe, T. and Taki, W. (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. British Journal of Ophthalmology, 95, 1245-1250. doi:10.1136/bjo.2010.194464
[18] Okada, A.A., Goto, H., Ohno, S. and Mochizuki, M. (2012) Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Archives of Ophthalmology, 130, 592-598. doi:10.1001/archophthalmol.2011.2698
[19] Cantini, F., Niccoli, L., Nannini, C., Kaloudi, O., Cassara, E., Susini, M., et al. (2012) Efficacy of infliximab in refractory Behcet’s disease-associated and idiopathic posterior segment uveitis: A prospective, follow-up study of 50 patients. Biologics, 6, 5-12.
[20] Ito, T., Sonoda, K.H., Hijioka, K., Fujimoto, T. and Ishibashi, T. (2010) Acquired resistance to infliximab against uveitis due to Behcet’s disease after one year of administration. Japanese Journal of Ophthalmology, 54, 502-504. doi:10.1007/s10384-010-0859-0
[21] Suhler, E.B., Smith, J.R., Wertheim, M.S., Lauer, A.K., Kurz, D.E., Pickard, T.D., et al. (2005) A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Archives of Ophthalmology, 123, 903-912. doi:10.1001/archopht.123.7.903
[22] Benitah, N.R., Sobrin, L. and Papaliodis, G.N. (2011) The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease. Seminars in Ophthalmology, 26, 295-303. doi:10.3109/08820538.2011.588665
[23] Fries, W., Giofre, M.R., Catanoso, M. and Lo Gullo, R. (2002) Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. The American Journal of Gastroenterology, 97, 499-500. doi:10.1111/j.1572-0241.2002.05514.x
[24] Ally, M.R., Veerappan, G.R. and Koff, J.M. (2008) Treatment of recurrent Crohn’s uveitis with infliximab. The American Journal of Gastroenterology, 103, 2150-2151. doi:10.1111/j.1572-0241.2008.01982_12.x
[25] Kruithof, E., Kestelyn, P., Elewaut, C., Elewaut, D., Van Den Bosch, F., Mielants, H., et al. (2002) Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Annals of the Rheumatic Diseases, 61, 470. doi:10.1136/ard.61.5.470
[26] Baraliakos, X., van den Berg, R., Braun, J. and van der Heijde, D. (2012) Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford), 51, 1378-1387. doi:10.1093/rheumatology/kes026
[27] El Maghraoui, A. (2011) Extra-articular manifestations of ankylosing spondylitis: Prevalence, characteristics and therapeutic implications. European Journal of Internal Medicine, 22, 554-560. doi:10.1016/j.ejim.2011.06.006
[28] Mangge, H., Heinzl, B., Grubbauer, H.M., El-Shabrawi, Y. and Schauenstein, K. (2003) Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatology International, 23, 258-261. doi:10.1007/s00296-003-0308-1
[29] Sharma, S.M., Ramanan, A.V., Riley, P. and Dick, A.D. (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: Efficacy in joint and ocular disease. Annals of the Rheumatic Diseases, 66, 840-841. doi:10.1136/ard.2006.065441
[30] Khalifa, Y.M., Bailony, M.R. and Acharya, N.R. (2010) Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab. Ocular Immunology and Inflammation, 18, 218-222. doi:10.3109/09273941003739910
[31] Sukumaran, S., Marzan, K., Shaham, B. and Reiff, A. (2012) High dose infliximab in the treatment of refractory uveitis: Does dose matter? ISRN Rheumatology, 2012, 765380.
[32] Farvardin, M., Afarid, M. and Shahrzad, S. (2012) Longterm effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. Journal of Ocular Pharmacology and Therapeutics, 28, 628-631. doi:10.1089/jop.2011.0199
[33] Markomichelakis, N., Delicha, E., Masselos, S. and Sfikakis, P.P. (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in behcet disease: A pilot study in 15 patients. American Journal of Ophthalmology, 154, 534-541. e1. doi:10.1016/j.ajo.2012.03.035
[34] Rudwaleit, M., Rodevand, E., Holck, P., Vanhoof, J., Kron, M., Kary, S., et al. (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Annals of the Rheumatic Diseases, 68, 696-701. doi:10.1136/ard.2008.092585
[35] Mushtaq, B., Saeed, T., Situnayake, R.D. and Murray, P.I. (2007) Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond), 21, 824-825. doi:10.1038/sj.eye.6702352
[36] Takase, K., Ohno, S., Ideguchi, H., Uchio, E., Takeno, M. and Ishigatsubo, Y. (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatology International, 31, 243-245. doi:10.1007/s00296-009-1178-y
[37] Kotaniemi, K., Saila, H. and Kautiainen, H. (2011) Longterm efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clinical Ophthalmology, 5, 1425-1429. doi:10.2147/OPTH.S23646
[38] Erckens, R.J., Mostard, R.L., Wijnen, P.A., Schouten, J.S. and Drent, M. (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe’s Archive for Clinical and Experimental Ophthalmology, 250, 713-720. doi:10.1007/s00417-011-1844-0
[39] Diaz-Llopis, M., Salom, D., Garcia-de-Vicuna, C., Cordero-Coma, M., Ortega, G., Ortego, N., et al. (2012) Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology, 119, 1575-1581.
[40] Leccese, P., Latanza, L., D’Angelo, S., Padula, A. and Olivieri, I. (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet’s disease to infliximab. Clinical and Experimental Rheumatology, 29, S93.
[41] Bawazeer, A., Raffa, L.H. and Nizamuddin, S.H. (2010) Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocular Immunology and Inflammation, 18, 226-232. doi:10.3109/09273948.2010.483314
[42] Dhingra, N., Morgan, J. and Dick, A.D. (2009) Switching biologic agents for uveitis. Eye, 23, 1868-1870. doi:10.1038/eye.2009.203
[43] Reiff, A., Takei, S., Sadeghi, S., Stout, A., Shaham, B., Bernstein, B., et al. (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis & Rheumatism, 44, 1411-1415. doi:10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO, 2-O
[44] Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., et al. (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis & Rheumatism, 48, 1093-1101. doi:10.1002/art.10885
[45] Reddy, A.R. and Backhouse, O.C. (2003) Does etanercept induce uveitis? British Journal of Ophthalmology, 87, 925. doi:10.1136/bjo.87.7.925
[46] Reiff, A. (2003) Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis & Rheumatism, 48, 2079-2080. doi:10.1002/art.11155
[47] Schmeling, H. and Horneff, G. (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology, 44, 1008-1011. doi:10.1093/rheumatology/keh658
[48] Taban, M., Dupps, W.J., Mandell, B. and Perez, V.L. (2006) Etanercept (enbrel)-associated inflammatory eye disease: Case report and review of the literature. Ocular Immunology and Inflammation, 14, 145-150. doi:10.1080/09273940600659393
[49] Lim, L.L., Fraunfelder, F.W. and Rosenbaum, J.T. (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis & Rheumatism, 56, 3248-3252. doi:10.1002/art.22918
[50] Gaujoux-Viala, C., Giampietro, C., Gaujoux, T., Ea, H.K., Prati, C., Orcel, P., et al. (2012) Scleritis: A paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. The Journal of Rheumatology, 39, 233-239. doi:10.3899/jrheum.110865
[51] Schafer, V.S. and Zwerina, J. (2012) Biologic treatment of large-vessel vasculitides. Current Opinion in Rheumatology, 24, 31-37. doi:10.1097/BOR.0b013e32834dc392
[52] Muselier, A., Bielefeld, P., Bidot, S., Vinit, J., Besancenot, J.F. and Bron, A. (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocular Immunology and Inflammation, 19, 382-383. doi:10.3109/09273948.2011.606593
[53] Shapiro, L.S., Farrell, J. and Haghighi, A.B. (2012) Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clinical Neurology and Neurosurgery, 114, 297-298. doi:10.1016/j.clineuro.2011.10.024
[54] Tappeiner, C., Heinz, C., Ganser, G. and Heiligenhaus, A. (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? The Journal of Rheumatology, 39, 1294-1295. doi:10.3899/jrheum.120010
[55] William, M., Faez, S., Papaliodis, G.N. and Lobo, A.M. (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. Journal of Ophthalmic Inflammation and Infection, 2, 231-233.
[56] Planck, S.R., Woods, A., Clowers, J.S., Nicklin, M.J., Rosenbaum, J.T. and Rosenzweig, H.L. (2012) Impact of IL-1 signalling on experimental uveitis and arthritis. Annals of the Rheumatic Diseases, 71, 753-760. doi:10.1136/annrheumdis-2011-200556
[57] Teoh, S.C., Sharma, S., Hogan, A., Lee, R., Ramanan, A.V. and Dick, A.D. (2007) Tailoring biological treatment: Anakinra treatment of posterior uveitis associated with the CINCA syndrome. British Journal of Ophthalmology, 91, 263-264.
[58] Gul, A., Tugal-Tutkun, I., Dinarello, C.A., Reznikov, L., Esen, B.A., Mirza, A., et al. (2012) Interleukin-1betaregulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: An open-label pilot study. Annals of the Rheumatic Diseases, 71, 563-566. doi:10.1136/annrheumdis-2011-155143
[59] Smith, K.G., Jones, R.B., Burns, S.M. and Jayne, D.R. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis & Rheumatism, 54, 2970-2982. doi:10.1002/art.22046
[60] Meijer, J.M., Pijpe, J., Vissink, A., Kallenberg, C.G. and Bootsma, H. (2009) Treatment of primary Sjogren syndrome with rituximab: Extended follow-up, safety and efficacy of retreatment. Annals of the Rheumatic Diseases, 68, 284-285. doi:10.1136/ard.2008.092601
[61] Smith, R.M., Jones, R.B., Guerry, M.J., Laurino, S., Catapano, F., Chaudhry, A., et al. (2012) Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis & Rheumatism, 64, 3760-3769. doi:10.1002/art.34583
[62] Nakken, B., Munthe, L.A., Konttinen, Y.T., Sandberg, A.K., Szekanecz, Z., Alex, P., et al. (2011) B-cells and their targeting in rheumatoid arthritis—Current concepts and future perspectives. Autoimmunity Reviews, 11, 28-34. doi:10.1016/j.autrev.2011.06.010
[63] Tappeiner, C., Heinz, C., Specker, C. and Heiligenhaus, A. (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Research, 39, 184-186. doi:10.1159/000103239
[64] Davatchi, F., Shams, H., Rezaipoor, M., Sadeghi-Abdollahi, B., Shahram, F., Nadji, A., et al. (2010) Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). International Journal of Rheumatic Diseases, 13, 246-252. doi:10.1111/j.1756-185X.2010.01546.x
[65] Heiligenhaus, A., Miserocchi, E., Heinz, C., Gerloni, V. and Kotaniemi, K. (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology, 50, 1390-1394. doi:10.1093/rheumatology/ker107
[66] Miserocchi, E. and Modorati, G. (2012) Rituximab for noninfectious uveitis. Developments in Ophthalmology, 51, 98-109. doi:10.1159/000336188
[67] Zulian, F., Balzarin, M., Falcini, F., Martini, G., Alessio, M., Cimaz, R., et al. (2010) Abatacept for severe antitumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care & Research, 62, 821-825. doi:10.1002/acr.20115

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.